New hepatitis C therapies: the toolbox, strategies, and challenges.
about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionHepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Hepatitis C virus: A time for decisions. Who should be treated and when?Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaVirologic Tools for HCV Drug Resistance TestingInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceA New Twist to a Chronic HCV Infection: Occult Hepatitis CHepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagyAging and liver diseaseHepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.Approved Antiviral Drugs over the Past 50 YearsHepatitis C Virus in North Africa: An Emerging ThreatDaclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysisAdvanced molecular surveillance of hepatitis C virusIdentification of a Novel Hepacivirus in Domestic Cattle from GermanyMetabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designOutcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case ReportAnti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingCharacterization of miR-122-independent propagation of HCV.Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?Drug interactions and antiretroviral drug monitoring.Autophagy in HCV infection: keeping fat and inflammation at bayNo strategy to meet the HCV epidemicIdentification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.Hepatitis C virus genotype 3: hope for nonresponders and patients with cirrhosis.FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.Health care-associated hepatitis C virus infection.Hepatitis C virus life cycle and lipid metabolismNatural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro.Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.Labour productivity losses caused by premature death associated with hepatitis C in Spain.A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3.
P2860
Q26746563-08A945BD-F562-4247-BCFD-724D4E7CF529Q26750997-99C41F61-E957-480A-8D6B-F37BF4220DCEQ26768274-F87EF288-9D15-4EE2-B554-CF232E5746D9Q26773251-F946B95F-6314-47A5-AA13-43A551429927Q26774374-0CC2ACA5-8BBD-4D2F-8417-345793470514Q26781331-53167392-AB39-4E0C-AA63-43F8482C3EA9Q26798189-AEA1F0ED-2D7D-4E48-B978-381A7D02D923Q26801207-3655ADAE-FA8E-4CB9-AA5B-C1BC85A6FD6AQ26852595-948988C7-B979-4441-BAE3-3F1849075394Q27321791-31B12BF0-C287-48BD-9ACA-34A9B00DD151Q27755387-7105BCB5-E23D-48E3-8F51-ADF568A7FD58Q28069590-BCEA1B0F-E9B4-4195-A9DC-A510D968AFBCQ28073108-C1387F25-83CA-47B5-B6EA-0139E8A7A551Q28650908-7C4FCD11-E0B7-4867-8A15-3108D771343DQ29035744-68D04AEA-646C-47D9-9881-97F3ABFCC9C6Q30369757-96C3C345-458B-45D4-BB7C-BD9CE2EEA9B8Q30374314-85D6762D-8EC9-4605-9FB9-20EA15C9C155Q30376341-8907D891-AB77-4BF8-8420-A61F9581FEF2Q33425472-606FEDE0-A34F-4246-8A92-289E5AE62B93Q33601691-3913F69A-AF58-41A6-BF8A-1459217DD54CQ33646482-1D3D69CD-BA7A-452D-B50F-338E0A07DE61Q33719172-FDBFDB5B-ED1F-4B61-8A80-6736A5A9A84DQ33805907-7F60A9A9-FCC4-42B1-8C9B-244BF12093C8Q33978118-C1851CCB-030D-4196-B78D-F82047B1C968Q34021173-25D40D5A-503E-475E-A902-1D0DA34E4718Q34069393-0EF8EA95-B670-4437-B634-F82C8E937D6CQ34260680-A0832C82-5A91-46C8-AA81-247B80469104Q34262175-2C9116E3-56CE-442A-BB45-35B9AAA97FC6Q34302745-C91730E5-8DCE-44EF-A0D0-56744490F56EQ34474404-DDDCCB2F-031F-44EB-A8A8-8EB79DFAE366Q34696503-E7AD44C9-CE38-4678-B615-047FD8ACEDECQ34792436-C5CEAEF4-9A68-4E6F-8840-AF11FFBF5240Q35087842-2B9BEE60-87FE-4DF2-85E8-DCF2792ABB03Q35228316-F7019B19-5AF7-4C2F-8EFA-01FADAED42E4Q35237179-DFBC015F-E4BD-4323-9109-FDF6A66E5757Q35501190-CCF70D29-D755-46B3-8653-D111714ED9AEQ35558268-67F74CEE-35B8-466C-9850-51F7317F1F48Q35579175-6597C1F0-6236-4556-AB8A-02C0A460DA9EQ35598309-2E7A0044-293E-4FCE-83B6-FB92B9F269E1Q35598686-16F76F2A-6DBB-42B2-A199-B18E287866E9
P2860
New hepatitis C therapies: the toolbox, strategies, and challenges.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New hepatitis C therapies: the toolbox, strategies, and challenges.
@en
type
label
New hepatitis C therapies: the toolbox, strategies, and challenges.
@en
prefLabel
New hepatitis C therapies: the toolbox, strategies, and challenges.
@en
P1433
P1476
New hepatitis C therapies: the toolbox, strategies, and challenges.
@en
P2093
Jean-Michel Pawlotsky
P304
P356
10.1053/J.GASTRO.2014.03.003
P407
P577
2014-03-12T00:00:00Z